Veterans study to reveal best prostate cancer pill

NCT ID NCT05422911

Recruiting now Disease control Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing three different drugs—abiraterone acetate, enzalutamide, and apalutamide—in 192 veterans with castrate-sensitive prostate cancer that has spread. The goal is to see which drug works best as a first treatment when combined with hormone therapy. Researchers will measure tumor growth rates and PSA levels to compare effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone acetate, enzalutamide, or apalutamide
What this could lead to: If successful, this study could help identify which of these three drugs is most effective for veterans with prostate cancer, potentially improving treatment choices and outcomes.
What could go wrong: This is a phase 2 trial with only 192 participants, so results may not apply to all patients. The study is also observational in part, so it may not prove one drug is definitively better than another.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATE SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis prostate cancer prostate carcinoma prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATE SENSITIVE PROSTATE CANCER CASTRATE-SENSITIVE METASTATIC CANCER NEOPLASM, PROSTATE

Contacts and locations

Locations

Corporal Michael J. Crescenz VA Medical Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
James A. Haley Veterans Administration Hospital
RECRUITING

Tampa, Florida, 33612, United States
James J. Peters VA Medical Center
RECRUITING

The Bronx, New York, 10468, United States
Michael E. DeBakey VA Medical Center
RECRUITING

Houston, Texas, 77030, United States
VA Ann Arbor Healthcare System
RECRUITING

Ann Arbor, Michigan, 48105, United States
VA Greater Los Angeles Healthcare System
RECRUITING

Los Angeles, California, 90073, United States
VA Hudson Valley Health Care System
RECRUITING

Wappingers Falls, New York, 12590, United States
VA New York Harbor Healthcare System
RECRUITING

New York, New York, 10010, United States
VA Portland Health Care System
RECRUITING

Portland, Oregon, 97239, United States
VA Puget Sound Health Care System
RECRUITING

Seattle, Washington, 98108, United States
VA St. Louis Health Care System
RECRUITING

St Louis, Missouri, 63106, United States
W.G. Bill Hefner Medical Center
RECRUITING

Salisbury, North Carolina, 28144, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.